SHOULDER, METAL/POLYMER ELBOW PROSTHESES AND PLASTER OF PARIS SHOULD GET CLASS II STATUS, WITH METAL/METAL ELBOWS REMAINING IN CLASS III -- ORTHOPEDIC PANEL
This article was originally published in The Gray Sheet
Shoulder and metal/polymer elbow prostheses should be downclassified to Class II, FDA's Orthopedic Devices Panel concluded at a Jan. 12 meeting in Gaithersburg, Maryland. However, the advisory committee recommended that metal/metal elbow prostheses remain in Class III, given a lack of data on the novel devices.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.